Lexeo Therapeutics Inc. (LXEO)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript
Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript
Lexeo Therapeutics's LX2006 Has A Viable Regulatory Pathway And Timeline
Lexeo Therapeutics is a clinical-stage gene therapy company focused on inherited cardiac diseases. Their main value driver is LX2006 for Friedreich's ataxia (FA) cardiomyopathy. LX2006 currently has a clearer SUNRISE-FA 2 pivotal path, and we should get its topline data by 2H2027.
Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcript
Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcript
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $19.00 Consensus Target Price from Analysts
Shares of Lexeo Therapeutics, Inc. (NASDAQ: LXEO - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the ten brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and one has assigned a strong buy
Lexeo Therapeutics, Inc. (LXEO) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Lexeo Therapeutics, Inc. (LXEO) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Lexeo Therapeutics, Inc. (LXEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript
Lexeo Therapeutics, Inc. (LXEO) Discusses Preliminary Data From Phase I/II Trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript
Lexeo Therapeutics, Inc. (LXEO) Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript
Lexeo Therapeutics, Inc. (LXEO) Clinician Perspectives on Holistic Management of PKP2-Associated Arrhythmogenic Cardiomyopathy Transcript
Wall Street Analysts Predict a 124.3% Upside in Lexeo Therapeutics, Inc. (LXEO): Here's What You Should Know
The consensus price target hints at a 124.3% upside potential for Lexeo Therapeutics, Inc. (LXEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement
Lexeo Therapeutics, Inc. established further positive interim data from phase 1/2 SUNRISE-FA study using LX2006 for the treatment of patients with Friedreich's Ataxia Cardiomyopathy. Pivotal LXEO registration study of LX2006 for the treatment of patients with Friedreich's Ataxia expected to start in 2026, with data release possible in 2027. The global Friedreich's Ataxia market is projected to reach $3.49 billion by the end of 2034.
Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further
Lexeo Therapeutics, Inc. achieved positive results across two studies using LX2006 for the treatment of patients with Friedreich's Ataxia Cardiomyopathy; Clinically meaningful improvements observed in several cardiac biomarkers. The global Friedreich's ataxia market is expected to reach $3.39 billion by 2034. Additional interim results, along with cardiac biopsy assessment in FA patients with LX2006, expected at an upcoming medical conference presentation in Fall of 2024.
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
Interim data from an early-stage study shows that treatment with Lexeo's (LXEO) experimental gene therapy reduced signs of heart complications in patients with Friedreich's ataxia.
